{"prompt": "['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', '2.3.', 'Tertiary Objective', 'To assess additional efficacy and safety parameters, PD and immunogenicity.', 'Definitions', 'An \"MG-ADL responder\" is defined as a patient who shows a decrease of at least 2 points on', 'the total MG-ADL score (compared to the corresponding Treatment Cycle Baseline [TCB])', 'for at least 4 consecutive weeks with the first of these decreases occurring at the latest 1 week', 'after last infusion of IMP of the corresponding cycle. The scoring of MG-ADL should be', 'performed by a trained and certified evaluator.', 'A \"QMG responder\" is defined as a patient who shows a decrease of at least 3 points on the', 'total QMG score (compared to the corresponding TCB) for at least 4 consecutive weeks with', 'the first of these decreases occurring at the latest 1 week after last infusion of IMP of the', 'corresponding cycle. The scoring of QMG should be performed by a trained evaluator.', 'An \"early MG-ADL responder\" is defined as a patient who shows a decrease of at least', '2 points on the total MG-ADL score (compared to the corresponding TCB) for at least', '4 consecutive weeks with the first of these decreases occurring after 1 or maximum 2 infusions', 'of IMP of the corresponding cycle. The scoring of MG-ADL should be performed by a trained', 'and certified evaluator.', 'An MG-ADL \"clinically meaningful improvement\" is defined as a decrease of at least 2 points', 'on the total MG-ADL score compared to either Study Entry Baseline (SEB) or corresponding', 'TCB.', 'A QMG \"clinically meaningful improvement\" is defined as a decrease of at least 3 points on', 'the total QMG score compared to either SEB or corresponding TCB.', '3.', 'TRIAL ENDPOINTS', '3.1.', 'Primary Endpoint', 'Percentage of patients who, after the first Treatment Cycle, have a decrease of at least', '2 points on the total MG-ADL score (compared to TC1B) for at least 4 consecutive', 'weeks with the first of these decreases occurring at the latest 1 week after the last', 'infusion of the IMP in the active versus placebo group in AChR-Ab seropositive', 'patients.', '3.2.', 'Secondary Endpoints', 'Percentage of patients who, after the first Treatment Cycle, have a decrease of at least', '3 points on the total QMG score (compared to TC1B) for at least 4 consecutive weeks', 'argenx BVBA', 'Confidential', 'Page 49 of 110']['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', 'with the first of these decreases occurring at the latest 1 week after the last infusion of', 'the IMP in the active versus placebo group in AChR-Ab seropositive patients.', 'Percentage of patients who, after the first Treatment Cycle, have a decrease of at least', '2 points on the total MG-ADL score (compared to TC1B) for at least 4 consecutive', 'weeks with the first of these decreases occurring at the latest 1 week after the last', 'infusion of the IMP in the active versus placebo group in the overall population', '(AChR-Ab seropositive and AChR-Ab seronegative patients).', 'Percentage of time that patients have a \"clinically meaningful improvement\" in total', 'MG-ADL score compared to SEB during the trial (up to and including Day 126) in the', 'active versus placebo group in AChR-Ab seropositive patients.', 'Time from TC1V5 to qualification for re-treatment, as assessed by monitoring the total', 'MG-ADL score (compared to TC1B), in the active versus placebo group in the AChR-', 'Ab seropositive patients.', 'Percentage of patients who, after the first Treatment Cycle, show a decrease of at least', '2 points on the total MG-ADL score (compared to TC1B) for at least 4 consecutive', 'weeks with the first of these decreases occurring at the latest after 1 or maximum', '2 infusions of the IMP in the active versus the placebo group in AChR-Ab seropositive', 'patients.', '3.3.', 'Tertiary Endpoints', 'Percentage of patients who, from the second Treatment Cycle on, have a decrease of at', 'least 2 points on the total MG-ADL score (compared to each corresponding TCB) for', 'at least 4 consecutive weeks with the first of these decreases occurring at the latest', '1 week after the last infusion of the IMP in the active versus placebo group in', 'AChR-Ab seropositive patients.', 'Percentage of patients who, from the second Treatment Cycle on, have a decrease of at', 'least 3 points on the total QMG score (compared to each corresponding TCB) for at', 'least 4 consecutive weeks with the first of these decreases occurring at the latest 1 week', 'after the last infusion of the IMP in the active versus placebo group in AChR-Ab', 'seropositive patients.', 'Percentage of patients who, from the second Treatment Cycle on, have a decrease of at', 'least 2 points on the total MG-ADL score (compared to each corresponding TCB) for', 'at least 4 consecutive weeks with the first of these decreases occurring at the latest', '1 week after last infusion of the IMP in the active versus placebo group in the overall', 'population (AChR-Ab seropositive and AChR-Ab seronegative patients).', 'Percentage of time that patients have a \"clinically meaningful improvement\" in total', 'MG-ADL score compared to SEB during the trial (up to and including Day 126) in the', 'argenx BVBA', 'Confidential', 'Page 50 of 110']\n\n###\n\n", "completion": "END"}